The Quantellect read.As of Nov 19, 2026, 16 active firms cover Intellia Therapeutics Inc: 7 rate it Buy or better, 6 sit at Neutral, and 3 rate it Sell or worse, a neutral consensus. The target range is very wide, $8.00 to $49.00 (about 6.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $20.63 sits 111% above the current $9.78. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.83 next quarter toward $-2.70 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 active firms
Neutral
Strong Buy00%
Buy744%
Neutral638%
Sell319%
Strong Sell00%
Based on 16 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$20.63
+110.9% upside
Average target across 16 active firms as of Nov 19, 2026 vs $9.78 current
Highest Target$49.00
Average Target$20.63
Lowest Target$8.00
Detailed analyst forecasts for NTLA
Showing 1–16 of 16 named analysts shown · 16 active firms in the rating projection
As of Nov 19, 2026, 7 of 16 active firms rate NTLA a Buy (6 Neutral, 3 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NTLA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.83
Range $-0.94 – $-0.56 · 8 analysts · +2% YoY
Next period, 8 analysts expect Intellia Therapeutics Inc to earn $-0.83 a share (range $-0.94 – $-0.56), versus $-0.81 a year earlier. Full-year consensus is $-3.27, growing to $-2.70 the year after.
REVENUE · NEXT QUARTER
$11.0M
Range $7.0M – $17.0M · 8 analysts · -27% YoY
Revenue is expected to reach $11.0M (range $7.0M – $17.0M), -27.0% year-over-year. Full-year consensus is $43.3M, rising to $119.0M next year.
Top analysts covering Intellia Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NTLA.
#1
David Nierengarten
Wedbush · Rank #24
Neutral
$13.00+32.9% to target
Overall win rate
48%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #69
Buy
$30.00+206.7% to target
Overall win rate
51%
+ Follow
#3
Luca Issi
RBC Capital · Rank #76
Neutral
$15.00+53.4% to target
Overall win rate
49%
+ Follow
#4
Brian Cheng
JP Morgan · Rank #87
Sell
$9.00-8.0% to target
Overall win rate
51%
+ Follow
#5
Geulah Livshits
Chardan Capital · Rank #104
Buy
$30.00+206.7% to target
Overall win rate
43%
+ Follow
NTLA stock forecast FAQ
What is NTLA's average 12-month price target?+
The 16 active firms with a live target average $20.63 for Intellia Therapeutics Inc over the next 12 months, ranging from a $49.00 high to a $8.00 low, as of Nov 19, 2026.
Is NTLA stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 16 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 6 rate it Neutral, and 3 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NTLA?+
The Street-high target is $49.00 (Canaccord Genuity), and the Street-low is $8.00 (Barclays). The average of all 16 active-firm targets is $20.63.
How many active Wall Street firms cover NTLA?+
16 active firms have a recognized rating on Intellia Therapeutics Inc as of Nov 19, 2026, and 16 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NTLA?+
Among analysts who currently cover NTLA, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Neutral with a $13.00 target.
What is Intellia Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.83 per share (range $-0.94 – $-0.56) across 8 analysts. Full-year EPS is projected at $-3.27, rising to $-2.70 the following year.
How much revenue is Intellia Therapeutics Inc expected to report next quarter?+
Consensus revenue is $11.0M (range $7.0M – $17.0M). Full-year revenue is projected at $43.3M, growing to $119.0M next year.
Have analysts been upgrading or downgrading NTLA lately?+
As of Nov 19, 2026, 7 of 16 active firms rate NTLA a Buy (6 Neutral, 3 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NTLA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.